SA
CLDX icon

Strategic Advocates’s Celldex Therapeutics CLDX Stock Holding History

Strategic Advocates’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130
Closed -$3.44K – 319
2025
Q4 		$3.44K Hold
130
– – ﹤0.01% 457
2025
Q3 		$3.36K Buy
+130
New +$3.01K ﹤0.01% 444

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Strategic Advocates's CLDX Position: Q1 2026 in Review

Strategic Advocates sold out of Celldex Therapeutics (CLDX) in Q1 2026, closing a stake of 130 shares — an estimated $3.44K sold.

Strategic Advocates first reported a position in CLDX in Q3 2025 and held it in 2 quarters. The position peaked at $3.44K in Q4 2025. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Strategic Advocates reported no remaining Celldex Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Strategic Advocates sold 130 Celldex Therapeutics shares in Q1 2026, an estimated $3.44K.
  • Strategic Advocates first reported a position in Celldex Therapeutics in Q3 2025 and held it in 2 quarters.
  • Strategic Advocates's Celldex Therapeutics position peaked at $3.44K in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.